IPP Bureau
Rossari Biotech Q1 FY23 revenue up 88%; Profit up 17%
By IPP Bureau - August 08, 2022
Profit after Tax (PAT) was up 18% for Q1 FY23 to reach Rs. 28.7 crore whereas EBITDA was up 52% to reach Rs. 57.7 crore
Thermo Fisher to expand dry powder media manufacturing facility in New York
By IPP Bureau - August 05, 2022
With this expansion, the Grand Island site provides redundant capacity to support global supply of media and further extends the site’s capabilities to produce the high-quality technology and materials needed for the development and commercial manufacturing of vaccines and biologic therapies
Tosoh to increase production capacity of separation and purification media
By IPP Bureau - August 05, 2022
Company will invest approximately ¥16 billion to increase production capacity by approximately 70% to ensure a stable supply
Lupin Q1 FY23 consolidated loss drops to Rs. 89.08 Cr
By IPP Bureau - August 04, 2022
Lupin is the 6th largest company in the Indian Pharmaceutical Market
Zydus receives final approval from the USFDA for Ivermectin Cream
By IPP Bureau - August 04, 2022
Ivermectin Cream is a used for the treatment of inflammatory lesions of rosacea.
Merck KGaA posts higher earnings, profits across business segments
By IPP Bureau - August 04, 2022
Despite the price increases for raw materials and logistics, EBITDA pre rose organically by 3.2% to € 1,782 million
Creoptix launches new WAVEcontrol to deliver automated and label-free analysis for biologics drug-discovery
By IPP Bureau - August 04, 2022
The WAVEsystem with the WAVEcontrol 4.0 embedded
Poly Medicure Q1FY23 consolidated PAT drops to Rs. 26.96 Cr
By IPP Bureau - August 04, 2022
The company has reported total income of Rs. 253.42 crores during the period ended June 30, 2022.
Sandu Pharmaceuticals launches Sandu Kumarvin
By IPP Bureau - August 04, 2022
Sandu Kumarvin is an Ayurvedic digestive and immunity booster for children and also offers several other benefits.
Merck and Eisai provide update on Phase 3 LEAP-002 trial evaluating KEYTRUDA
By IPP Bureau - August 04, 2022
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
LYNPARZA approved in the EU as adjuvant treatment for early breast cancer
By IPP Bureau - August 04, 2022
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients
Fortis Malar Hospitals posts Q1 FY2023 consolidated loss at Rs. 2.96 Cr
By IPP Bureau - August 03, 2022
The company has reported total income of Rs. 21.73 crores during the period ended June 30, 2022.
Jubilant Pharmova posts Q1FY23 consolidated PAT at Rs. 47.04 Cr
By IPP Bureau - August 03, 2022
The company has reported total income of Rs. 1463.03 crores during the period ended June 30, 2022.
Shivalik Rasayan Ltd inks marketing agreement with China Chinopharma
By IPP Bureau - August 03, 2022
The CSC shall hold Market Authorisation (MA) to sell SRL's BUSALFAN, API exclusively in China territory.
PIB: Quality control of Ayush drugs
By IPP Bureau - August 03, 2022
